Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biogen Inc. (BIIB) is conducting a Phase 3 long-term extension study titled A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus. The study aims to assess the long-term safety and efficacy of litifilimab in adults with active systemic lupus erythematosus (SLE), focusing on adverse events and symptom control.
The intervention involves the drug litifilimab, administered as subcutaneous injections every four weeks. The purpose is to evaluate its safety and effectiveness in reducing SLE symptoms and maintaining low disease activity.
The study design is interventional, with a randomized, parallel assignment. It employs quadruple masking to ensure unbiased results, and its primary purpose is treatment-focused.
The study began on June 10, 2022, with an estimated completion date in August 2025. These dates are crucial for tracking the study’s progress and potential market impact.
The update on this study could positively influence Biogen’s stock performance, as successful results may enhance investor confidence. Competitors in the lupus treatment market will be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.